dml meta-analysis v.1.3

8/20/2019 DML Meta-Analysis v.1.3

http://slidepdf.com/reader/full/dml-meta-analysis-v13 1/7

Intraoperative Fluid Management (IOFM)technologies and patient outcome:

a meta-analysis."#$$%&&' ()

)

*$ "#$$%&& +,-.&%/%0 1%$ 21* 34 21563,&,75 8/ 9%: ;%8&840<6 =43>%$63/5 ,? @/87,' #6347 *,..&%$ #&/$86,#40 840 22AB/%+14,&,73%6 /, 6/#05 /1% +,4/$,& ,? C&,,0 ?&,:D E%$ +#$$%4/ $,&% 36 F+3%4/36/ G%+/#$%$ :3/1 *%&/%H "%03+8&' .$,>303476+3%4/3?3+ %0#+8/3,4 840 6#..,$/ ,4 I@J"D

B 6#C6/84/38& C,05 ,? %>30%4+% %H36/6 /, 6#..,$/ /1% #6% ,? 34/$8,.%$8/3>% ?&#30

-8487%-%4/ KI@J"L' :13+1' 186 $%6#&/%0 34 /1% .$,+%66 ?,$-347 ,4% ,? /1% +,$%

+,-.,4%4/6 ,? M4184+%0 N%+,>%$5 .$,7$8--%6D O1% 83-6 ,? /136 -%/8P848&5636 :%$%/, $%>3%: /1% %>30%4+% ?,$ I@J" #6347 8 FQ ,./3-368/3,4 KFQ@L 8&7,$3/1-' 840

0%/%$-34% :1%/1%$ /1% ,#/+,-%6 :%$% +,-.8$8C&% 8+$,66 /%+14,&,73%6D @>%$8&&' I@J"

$%6#&/%0 34 63743?3+84/ $%0#+/3,46 34 /1% 34+30%4+% ,? .,6/,.%$8/3>% +,-.&3+8/3,46R

1,:%>%$' /1% %??%+/ :86 4,/ +,4636/%4/ 8+$,66 /%+14,&,73%6D F/#03%6 #6347 /1%

,%6,.187%8& *,..&%$ K@*"L ?,$ I@J" 0%-,46/$8/%0 8 $%0#+/3,4 34 /1% 34+30%4+% ,?

.,6/,.%$8/3>% +,-.&3+8/3,46 K@NS TDUUVR 2WTDTT)L' :1%$%86 6/#03%6 #6347 FQ@P7#30%0

I@J" :3/1 84 8$/%$38& .$%66#$% C86%0 0%>3+% K22ABL 030 4,/ K@NS TDXTVR 2YTDTZTLD

F3-3&8$&5' 08/8 ?$,- @*"P7#30%0 I@J" 0%-,46/$8/%0 8 )D)P085 $%0#+/3,4 34 &%47/1 ,?

1,6.3/8& 6/85 K2YTDTTZL' 84 ,#/+,-% 4,/ ,C6%$>%0 :3/1 22AB /%+14,&,73%6 KPTDU 0856K2YTD)UTLD O1% $%6#&/6 ,? /136 848&5636 3403+8/% 03??%$%4+%6 34 /1% %??3+8+5 ,? /1%

/%+14,&,73%6 #6%0 ?,$ I@J"D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ \] *%&/%H "%03+8& \T)U

B >8$3%/5 ,? /%+14,&,73%6 8$% #6%0 0#$347 6#$7%$5 ?,$

I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L' %8+1

#/3&36347 8 03??%$%4/ -%/1,0 K:3/1 03??%$347 8++#$8+5840 .$%+363,4L ?,$ -%86#$347 ,$ 0%$3>347 C&,,0 ?&,:D

I4 "8$+1 \T))' 9I(M $%+,--%40%0 /18/ /1% (8$03,^P

@*" _61,#&0 C% +,4630%$%0 ?,$ #6% 34 .8/3%4/6

#40%$7,347 -8`,$ ,$ 1371P$36a 6#$7%$5 ,$ ,/1%$ 6#$73+8&

.8/3%4/6 34 :1,- 8 +&343+384 :,#&0 +,4630%$ #6347

34>863>% +8$03,>86+#&8$ -,43/,$347b c)dD

F#C6%e#%4/&5' /1% 9EF I44,>8/3,4' E%8&/1' 840

A%8&/1 $%.,$/ 30%4/3?3%0 @*" 86 ,4% ,? 63H 1371P

3-.8+/ 344,>8/3,46 /18/ 61,#&0 C% 3-.&%-%4/%0 86

6/8408$0 +8$% c\dD O1% $%+%4/ 9EF M47&840 F/8408$0

(,4/$8+/ O%+143+8& f#3084+% ?,$ \T)Ug)h -8408/%6

/18/' C5 "8$+1 \T)h' 8&& 1,6.3/8&6 61,#&0 i0%-,46/$8/%

/, +,--3663,4%$6 /18/ /$8`%+/,$3%6 ?,$ /1%

I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6

8$% 34 .&8+% :13+1 8$% +,4636/%4/ :3/1 9OB( K4,: /1%

E%8/1 O%+14,&,75 B0,./3,4 2$,7$8--%LiD

O1% .#$.,6% ,? /136 -%/8P848&5636 :86 /, 34+&#0% /1%

-,6/ $%+%4/ 6/#03%6 840 C$347 #. /, 08/% /1% %>30%4+%

?,$ I@J" 86 7#30%0 C5 8 )Tj F/$,a% Q,&#-%

@./3-368/3,4 KFQ@L 8&7,$3/1-D (%08$ +,40#+/%0 84

340%.%40%4/ 866%66-%4/ ,? I@J" /%+14,&,73%6 34*%+%-C%$ \T)k' 1,:%>%$ 8 -%/8P848&5636 :86 4,/

34+&#0%0 34 /1%3$ $%.,$/ ckdD O1% )Tj FQ@ 8&7,$3/1-

:86 #6%0 34 /1% +&343+8& /$38&6 ,? @*" 840 :86 /1%

C8636 ,? /1% 9I(M $%+,--%408/3,4D

O1%$% 8$% /:, -834 8&7,$3/1-6 #6%0 /, 7#30% ?&#30

80-3436/$8/3,4 34 /1% 34/$8,.%$8/3>% %4>3$,4-%4/S FQ@'

840 /1% -343-368/3,4 ,? /1% $%6.3$8/,$5 >8$38/3,4 ,?

F/$,a% Q,&#-% ,$ 2#&6% 2$%66#$%' a4,:4 86 F/$,a%

Q,&#-% Q8$38/3,4 KFQQL ,$ 2#&6% 2$%66#$% Q8$38/3,4

K22QLD FQ@ 34>,&>%6 /1% 80-3436/$8/3,4 ,? 6-8&& K\TTP

\hT -GL C,&#6%6 ,? ?&#30' 840 /1% +,$$%6.,40347+1847% 34 FQ -%86#$%0D B +1847% lgW )Tj 3403+8/%6

/1% .8/3%4/ 36 18%-,0548-3+8&&5 $%6.,463>%g4,4P

$%6.,463>%D O136 -%/1,0 :86 0%6374%0 C86%0 ,4 /1%

.$%+363,4 K$%.%8/8C3&3/5L ,? /1% ,%6,.187%8& *,..&%$

K@*"LD B&/%$48/3>%&5' /1% -343-368/3,4 ,? FQQg22Q

34>,&>%6 /1% 80-3436/$8/3,4 ,? ?&#30 #4/3& /1%

.8$8-%/%$6 8$% W)TP)hjD

E,:%>%$' $%+%4/ %>30%4+% e#%6/3,46 /1% 68?%/5 ,? /1%

>8&30 #6% ,? FQQg22Q ?,$ I@J" cUdD @4% ,? /1%

$%e#3$%-%4/6 ?,$ $%&38C&% FQQg22Q -%86#$%-%4/ 36 8

/308& >,&#-% lZ -Gga7D B J$%4+1 -#&/3P+%4/$% 6/#05

?,#40 8 VTj $%0#+/3,4 34 .,6/,.%$8/3>% +,-.&3+8/3,46'

840 /:,P085 $%0#+/3,4 34 &%47/1 ,? 1,6.3/8& 6/85 :1%4

8 .$,/%+/3>% >%4/3&8/3,4 6/$8/%75 K/308& >,&#-% Y V

-Gga7L :86 #6%0 ,>%$ 8 4,4P.$,/%+/3>% >%4/3&8/3,4

6/$8/%75 K/308& >,&#-% Y )T -Gga7L 34 .8/3%4/6

#40%$7,347 8C0,-348& 6#$7%$5D D

O1% 83- ,? /136 -%/8P848&5636 :86 /, $%>3%: /1%

+&343+8& ,#/+,-% %>30%4+% ?,$ I@J"' 86 7#30%0 C5

FQ@' ,4 8 /%+14,&,75P6.%+3?3+ C8636D O1% $%.,$/

34+&#0%6 .#C&361%0g.%%$P$%>3%:%0 N(O6 840 8#03/

6/#03%6 :1%$% 0%>3+% %??3+8+5 :86 %>8&#8/%0 C5

+,-.8$347 /%+14,&,75P7#30%0 I@J" :3/1 8 +,4/$,&

7$,#. K/5.3+8&&5 6/8408$0 +8$%LD F/#05 08/8 ,4 /:,

,#/+,-% -%86#$%6 K34+30%4+% ,? .,6/,.%$8/3>%

+,-.&3+8/3,46' 840 &%47/1 ,? 1,6.3/8& 6/85 KG@FLL :%$%

+,-.8$%0D

The main technologies used for IOFM are:

@%6,.187%8& *,..&%$ K@*"L'

2#&6% 2$%66#$% A8>%?,$- B48&5636 K22ABL m +,&&%+/3>% /%$- ?,$ 8&& /%+14,&,73%6 /18/ 0%$3>% ?&,: ?$,-

/1% 8$/%$38& .$%66#$% :8>%?,$-' 34+&#0347S

o M0:8$06 Q373&%,gJ&,O$8+

o G3*(@.&#6 840 G3*(@$8.30

o 23((@ 840 2#&63,J&%H

n3,3-.%084+%g9I(@" n3,$%8+/84+%D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ k] *%&/%H "%03+8& \T)U

I4 /,/8&' \h 6/#03%6 :%$% 30%4/3?3%0 C86%0 ,4 /1% 8?,$%-%4/3,4%0 +$3/%$38D B &36/ ,? /1%6% 6/#03%6 36 0%/83&%0

C%&,:D

Table 1: I@J" 6/#03%6 34+&#0%0 34 -%/8P848&5636

B#/1,$' o%8$ O%+14,&,75F/#05O5.%

I@J" B&7,$3/1-

N%.,$/2,6/,.%$8/3>%

(,-.&3+8/3,46p

N%.,$/G@Fp

"5/1%4' )qqh chd @*" N(O FQ@ o o

F34+&83$' )qqX cVd @*" N(O FQ@ 9 o

(,4:85' \TT\ cXd @*" N(O FQ@ 9 o

Q%44' \TT\ cZd @*" N(O FQ@ o o

f84' \TT\ cqd @*" N(O FQ@ o o

A8a%&347' \TTh c)Td @*" N(O FQ@ o o

9,C&%//' \TTV c))d @*" N(O FQ@ o o

(18&&840' \T)) c)\d @*" N(O FQ@ o o

23&&83' \T)) c)kd @*" N(O FQ@ o o

n$8406/$#.' \T)\ c)Ud @*" N(O FQ@ o o

F$343>868' \T)\ c)hd @*" N(O FQ@ o o

M& F18$a8:5' \T)k c)Vd @*" N(O FQ@ o o

"+r%445' \T)k c)Xd @*" N(O FQ@ o o

;8a18&%>8' \T)k c)Zd @*" N(O FQ@ o o

r#.%$' \T)) c)qd @*" B#03/ FQ@ 9 o

J37#6' \T)) c\Td @*" B#03/ FQ@ 9 o

J%&01%36%$' \T)\ c\)d @*" B#03/ FQ@ 9 o

(18//,.801585' \T)k c\\d @*" B#03/ FQ@ o 9

"844,>8' \T)k c\kd @*" B#03/ FQ@ o o

"+r%445' \T)U c\Ud @*" B#03/ FQ@ o o

(%++,43' \T)) c\hd J&,O$8+ K22ABL N(O FQ@ o o

n8$/18' \T)\ c\VdG3*(@.&#6

K22ABLN(O FQ@ o o

n36788$0' \T)kP8 c\XdG3*(@.&#6

K22ABLN(O FQ@ o o

n36788$0' \T)kPC c\ZdG3*(@.&#6

K22ABLN(O FQ@ o o

2%8$6%' \T)U c\qd s G3*(@$8.30

K22ABLN(O FQ@ ot o

FQ@' F/$,a% Q,&#-% @./3-368/3,4D 9,/%S *8/8 ?$,- ,4% 30%4/3?3%0 6/#05 :%$% %H+&#0%0 ?$,- 848&5636 C%+8#6% ,?

03??3+#&/3%6 036+%$4347 /1% %??%+/ ,? /1% /%+14,&,75 >6D /1% %??%+/ ,? 6/#05 ?&#30 K6/#05 180 /:, /$%8/-%4/ 7$,#.6L ckTd s

2%$3,.%$8/3>% .$,/,+,& K/$%8/-%4/ 7$,#. $%+%3>%0 34/%$>%4/3,4 ?$,- C%7344347 ,? 6#$7%$5 #4/3& V 1 .,6/,.%$8/3>%&5LR u I4

8003/3,4 /, 0,C#/8-34%g0,.%H8-34% ?,$ *@\ /8$7%/R t (,-.,63/% ,? kTP085 -,$/8&3/5 840 -,0%$8/% ,$ -8`,$ .,6/,.%$8/3>%

+,-.&3+8/3,46D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ U] *%&/%H "%03+8& \T)U

O1%$% :86 &8$7% >8$384+% 34 /1% -%/1,0 ,?

$%.,$/347 .,6/,.%$8/3>% +,-.&3+8/3,46 :3/134 /1%

6/#03%6D *8/8 ,4 /1% v4#-C%$ ,? .8/3%4/6 :3/1+,-.&3+8/3,46w :86 ?8>,#$%0' :3/1 v/,/8& 4#-C%$ ,?

+,-.&3+8/3,46w %H/$8+/%0 3? /1% ?,$-%$ :%$% 4,/

8>83&8C&%D

9, .#C&361%0g.%%$P$%>3%:%0 6/#03%6 :%$% 30%4/3P

?3%0 #6347 /1% 23((@' 2#&63,J&%H' ,$ 9I(@"

/%+14,&,73%6 ?,$ I@J"' 840 /1%$%?,$% /1%6%

/%+14,&,73%6 +,#&0 4,/ C% 34+&#0%0 34 /1% 848&5636D

*8/8 8$% $%.,$/%0 86 v,006 $8/3,6 K@NLw ?,$

.,6/,.%$8/3>% +,-.&3+8/3,46' 840 v03??%$%4+% 34

-%846w ?,$ &%47/1 ,? 1,6.3/8& 6/85D B4 @N 36 8

-%86#$% ,? 84 866,+38/3,4 C%/:%%4 %H.,6#$% /,

/1% /$%8/-%4/ 840 ,#/+,-%D B4 @N W) 3403+8/%6

%H.,6#$% /, I@J" :86 866,+38/%0 :3/1 8 &,:%$ $36a

,? .,6/,.%$8/3>% +,-.&3+8/3,4D B&& 848&56%6 :%$%

+,40#+/%0 #6347 (,-.$%1%463>% "%/8PB48&56366,?/:8$% Kn3,6/8/ I4+D' =FBLD

Results: postoperative complications

B48&5636 ,? 8&& 6/#03%6 $%>%8&%0 8 63743?3+84/ %??%+/

,? I@J" 34 $%0#+347 +,-.&3+8/3,46 ?,&&,:347

6#$7%$5 K,006 $8/3, K@NLS TDhhXR 2WTDTT)LD O1% @N

?%&& /, TDUUV K2WTDTT)L :1%4 ,4&5 08/8 ?$,- @*"

6/#03%6 :%$% 34+&#0%0 KJ37#$% )L' 840 $,6% /, TDXTV

K2YTDTZTL :3/1 22AB /%+14,&,73%6 ,4&5D @>%$8&&

.8/3%4/6 :1, $%+%3>%0 FQ@P7#30%0 I@J" :3/1 /1%

@*" 8$% xhhj &%66 &3a%&5 /, 0%>%&,. 8

.,6/,.%$8/3>% +,-.&3+8/3,4 /184 /1,6% .8/3%4/6

:1, $%+%3>%0 $,#/34% ?&#30 -8487%-%4/D

Figure 1: "%/8P848&5636 ,? 6/#03%6 866%66347 /1% %??3+8+5 ,? FQ ,./3-368/3,4P7#30%0 I@J" :3/1 03??%$%4/

/%+14,&,73%6 ,4 .,6/,.%$8/3>% +,-.&3+8/3,46D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ h] *%&/%H "%03+8& \T)U

Results: length of hospital stay (LOS)

f$,#.%0 848&5636 $%>%8&%0 8 /$%40 /,:8$06 8

$%0#+/3,4 34 G@F :3/1 FQ@P7#30%0 I@J" KPTDV

0856R 2YTDTTZLD E,:%>%$' C5P/%+14,&,75 848&5636

$%>%8&%0 03??%$%4+%6 C%/:%%4 /1% /%+14,&,73%6D

=6% ,? @*" ?,$ I@J" $%0#+%0 G@F C5 )D) 0856

,4 8>%$87% K2YTDTTZR J37#$% \L' :1%$%86 6/#03%6

#/3&36347 FQ ,./3-368/3,4 ?,$ I@J" :3/1 22AB

/%+14,&,73%6 ?83&%0 /, 0%-,46/$8/% 63743?3+84/

$%0#+/3,46 34 G@F KPTDU 0856R 2YTD)UTLD

Figure 2: "%/8P848&5636 ,? 6/#03%6 866%66347 /1% %??3+8+5 ,? FQ ,./3-368/3,4P7#30%0 I@J" :3/1 03??%$%4/

/%+14,&,73%6 ,4 &%47/1 ,? 1,6.3/8& 6/85D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ V] *%&/%H "%03+8& \T)U

Conclusions B&/1,#71 7$,#.%0 08/8 $%>%8&%0 /18/ FQ

,./3-368/3,4P7#30%0 I@J" $%6#&/6 34 63743?3+84/

$%0#+/3,46 34 /1% 34+30%4+% ,? .,6/,.%$8/3>%

+,-.&3+8/3,46 840 &%47/1 ,? 1,6.3/8& 6/85' /1%$% 8$%

03??%$%4+%6 34 /1% %??3+8+5 ,? /1% +,--%$+38&&5

8>83&8C&% /%+14,&,73%6D O136 848&5636 $%>%8&6 /18/

/1% @*" 36 /1% ,4&5 I@J" /%+14,&,75 34 :13+1

6/#03%6 0%-,46/$8/% 63743?3+84/ $%0#+/3,46 34 C,/1

.,6/,.%$8/3>% +,-.&3+8/3,46 840 &%47/1 ,? 1,6.3/8&

6/85D

9#-%$,#6 6/#03%6 18>% $%.,$/%0 03??%$%4+%6

C%/:%%4 /1% I@J" /%+14,&,73%6' %6.%+38&&5 34 /1%3$$%6.,46% /, /5.3+8& 6#$73+8& 34/%$>%4/3,46 6#+1 86

?&#30 840 >86,8+/3>% 0$#7 80-3436/$8/3,4 ck)Pkkd'

840 -85 .$,>30% %H.&848/3,4 86 /, /1% 03??%$347

%??3+8+5 ,? /1% /%+14,&,73%6D

F+1&y7&1,?%$ %/ 8&D ckUd +,40#+/%0 8 -%/8P848&5636

+,-.8$347 ?3>% 22AB 656/%-6 840 /1%3$

87$%%-%4/ :3/1 /1%$-,03&#/3,4 (@D O1%5

+,4+&#0%0' _*%6.3/% +,4/34#%0 %??,$/6 /, 34/$,0#+%

3-.$,>%0 .$,0#+/6 /, /1% -8$a%/' /1% -834

,#/+,-% ,? ,#$ 848&5636 36 /18/ 8 +&%8$

$%+,--%408/3,4 +844,/ C% 73>%4 ?,$ 845 6347&%

656/%- /18/ +84 8++#$8/%&5 -,43/,$

1%-,0548-3+8&&5 #46/8C&% .8/3%4/6D O136 &3-3/8/3,4

8&6, 8..&3%6 /, $%&38C&% 34/$8,.%$8/3>% -,43/,$347

0#$347 6#$7%$5 8++,-.843%0 C5 1%-,0548-3+

346/8C3&3/5D O1% 34?,$-8/3>% >8&#% ,? .#&6% +,4/,#$P

C86%0 (@ -,43/,$347 0#$347 1%-,0548-3+8&&5

6/8C&% +,403/3,46 61,#&0 C% e#%6/3,4%0' 634+% (@

08/8 .$,>30%0 C5 /1%6% -,43/,$6 .8$8&&%& /1%

8$/%$38& .$%66#$% 86 &,47 86 /1% +,-.&384+% 840$%636/84+% $%-834 #48??%+/%0bD

E80384 %/ 8&D ckhd 8&6, +,-.8$%0 /%+14,&,73%6 840

+,4+&#0%0 _3? +&343+8& /$38&6 ,? $%6#6+3/8/3,4 C86%0

,4 (@ >8&#%6 61,: %??3+8+5 :1%4 #6347 ,4% ,?

/1%6% 0%>3+%6' 3/ 36 4,/ +&%8$ :1%/1%$ .%$?,$-347

/1% 30%4/3+8& /$38& :3/1 84,/1%$ (@ -,43/,$347

0%>3+% :3&& 8&6, 61,: 63-3&8$ C%4%?3/D O1#6' #4/3& /1%

87$%%-%4/ 8-,47 -343-8&&5 34>863>% (@

-%86#$347 0%>3+%6 3-.$,>%6' %8+1 0%>3+% 4%%06

/, 18>% 3/6 ,:4 +&343+8& %??3+8+5 >8&308/%0Db

O1% FQ@ 8&7,$3/1- 0%-,46/$8/%0 6#.%$3,$ %??3+8+5

:1%4 #6%0 :3/1 @*" /%+14,&,75D O136 8&7,$3/1-

:86 0%6374%0 ?,$ #6% :3/1 /1% @*" /%+14,&,75

C86%0 ,4 3/6 .$%+363,4' C%347 6#+1 /18/ /1% #6%$

+84 C% qqj +,4?30%4/ /18/ 8 -%86#$%0 +1847% 34

FQ ,? )Tj 36 3403+8/3>% ,? 8 $%8& +1847% 34 ?&,:

840 4,/ -%86#$%-%4/ %$$,$ ckVdD @/1%$

/%+14,&,73%6 :3/1 .,,$%$ .$%+363,4 8..%8$ /, C%

&%66 %??%+/3>% :1%4 #6347 /1% FQ@ 8&7,$3/1- ?,$

I@J"D B&/%$48/3>% -%/1,0,&,73%6 #6347

6#..$%663,4 ,? $%6.3$8/,$5 6:347 18>% &3-3/8/3,46 34.8/3%4/ 8..&3+8/3,4' :3/1 W)Tj ,? 6#$73+8& .8/3%4/6

-%%/347 /1% $%e#3$%-%4/6 ?,$ >8&30 #6% ,?

FQQg22Q ckXdD

O1% @*" 36 /1% ,4&5 /%+14,&,75 $%+,--%40%0 ?,$

FQ@P7#30%0 I@J" c)d' 8 $%+,--%408/3,4

6#..,$/%0 C5 /1% ?3403476 ,? /136 -%/8P848&5636D

D



I4/$8,.%$8/3>% J&#30 "8487%-%4/ KI@J"L /%+14,&,73%6 840 .8/3%4/ ,#/+,-%S 8 -%/8P848&5636D

287% [ X] *%&/%H "%03+8& \T)U

N%?%$%4+%6

)D NHS: National Institute for Health and Clinical Excellence.CardioQ-ODM Oesophageal Doppler Monitor.

1//.Sgg7#3084+%D43+%D,$7D#ag"Ofk' \T))D\D Innovation Health and Wealth: Accelerating Adoption and

Diffusion in the NHS. 1//.Sgg:::D01D7,>D#ag.#C&3+8/3,46' \T))DkD Cedar: Intraoperative Fluid Management TechnologiesD

1//.Sgg:::D+%08$D:8&%6D416D#ag0,+#-%4/g\\ZUUV' \T)kDUD J#/3%$' MD' %/ 8&D' A trial of intraoperative low-tidal-volume

ventilation in abdominal surgery. 9 M47& z "%0' \T)kD 369KhLS .DU\ZPkXD

hD "5/1%4' "DfD 840 BDND A%CC' Perioperative plasma volumeexpansion reduces the incidence of gut mucosal hypoperfusionduring cardiac surgery. B$+1 F#$7' )qqhD 130KULS .D U\kPqD

VD F34+&83$' FD' FD z8-%6' 840 "D F347%$' Intraoperativeintravascular volume optimisation and length of hospital stayafter repair of proximal femoral fracture: randomised controlledtrial. n"z' )qqXD 315KX))kLS .D qTqP)\D

XD (,4:85' *DED' @DBD E#66834' 840 ID f8&&' A comparison ofnoninvasive bioreactance with oesophageal Doppler estimationof stroke volume during open abdominal surgery: Anobservational study. M#$ z B48%6/1%63,&' \T)kD 30KZLS .D hT)PZD

ZD Q%44' ND' %/ 8&D' Randomized controlled trial to investigateinfluence of the fluid challenge on duration of hospital stay and perioperative morbidity in patients with hip fractures. n$ z B48%6/1' \TT\D 88K)LS .D VhPX)D

qD f84' ODzD' %/ 8&D' Goal-directed intraoperative fluid administrationreduces length of hospital stay after major surgery.

B4%6/1%63,&,75' \TT\D 97KULS .D Z\TPVD)TD A8a%&347' EDfD' %/ 8&D' Intraoperative oesophageal Doppler

guided fluid management shortens postoperative hospital stayafter major bowel surgery. n$ z B48%6/1' \TThD 95KhLS .D VkUPU\D

))D 9,C&%//' FDMD' %/ 8&D' Randomized clinical trial assessing theeffect of Doppler-optimized fluid management on outcome afterelective colorectal resection. n$ z F#$7' \TTVD 93KqLS .D )TVqPXVD

)\D (18&&840' (D' %/ 8&D' Randomized controlled trial of intraoperativegoal-directed fluid therapy in aerobically fit and unfit patientshaving major colorectal surgery. n$ z B48%6/1' \T)\D 108K)LS .DhkPV\D

)kD 23&&83' 2D' %/ 8&D' A double-blind randomized controlled clinical trialto assess the effect of Doppler optimized intraoperative fluidmanagement on outcome following radical cystectomy. z =$,&'\T))D 186KVLS .D \\T)PVD

)UD n$8406/$#.' nD' %/ 8&D' Which goal for fluid therapy duringcolorectal surgery is followed by the best outcome: near-maximal stroke volume or zero fluid balance? n$ z B48%6/1'\T)\D 109K\LS .D )q)PqD

)hD F$343>868' FD' %/ 8&D' Randomized clinical trial of goal-directedfluid therapy within an enhanced recovery protocol for elective

colectomy. n$ z F#$7' \T)kD 100K)LS .D VVPXUD)VD M& F18$a8:5' @DBD' %/ 8&D' Transoesophageal Doppler compared

to central venous pressure for perioperative hemodynamicmonitoring and fluid guidance in liver resection. F8#03 z

B48%6/1' \T)kD 7KULS .D kXZPZVD)XD "+r%445' "D' %/ 8&D' A randomised prospective trial of intra-

operative oesophageal Doppler-guided fluid administration inmajor gynaecological surgery. B48%6/1%638' \T)kD

)ZD ;8a18&%>8' zD' %/ 8&D' The impact of intravenous fluidadministration on complication rates in bowel surgery within anenhanced recovery protocol: a randomized controlled trial. (,&,$%+/8& *36' \T)kD 15KXLS .D Zq\PqD

)qD r#.%$' "D' %/ 8&D' Intraoperative fluid management guided byoesophageal Doppler monitoring. n"z' \T))D 342S .D 0kT)VD

\TD J37#6' BD' %/ 8&D' Intraoperative esophageal Doppler

hemodynamic monitoring in free perforator flap surgery. B442&86/ F#$7' \T)kD 70KkLS .D kT)PXD

\)D J%&01%36%$' BD' %/ 8&D' Development and feasibility study of analgorithm for intraoperative goal-directed haemodynamic

management in noncardiac surgery. z I4/ "%0 N%6' \T)\D 40KULS.D )\\XPU)D

\\D (18//,.801585' FD' %/ 8&D' The role of intraoperative fluidoptimization using the esophageal Doppler in advancedgynecological cancer: early postoperative recovery and fitnessfor discharge. I4/ z f54%+,& (84+%$' \T)kD 23K)LS .D )qqP\TXD

\kD "844,>8' zDED' %/ 8&D' Perioperative haemodynamic monitoringby oesophageal Doppler improves outcome of patients withabdominal aortic aneurysm repair. n$8/36& G%a G36/5' \T)kD114K\LS .D XZPZkD

\UD "+r%445' "D' %/ 8&D' Introduction of oesophageal Doppler-guidedfluid management in a laparoscopic colorectal surgery enhancedrecovery programme: an audit of effect on patient outcome. I$"%0 z' \T)UD 107KhLS .D )khPZD

\hD (%++,43' "D' %/ 8&D' Goal-directed haemodynamic therapy during

elective total hip arthroplasty under regional anaesthesia. ($3/(8$%' \T))D 15KkLS .D N)k\D\VD n8$/18' MD' %/ 8&D' Randomized controlled trial of goal-directed

haemodynamic treatment in patients with proximal femoralfracture. n$ z B48%6/1' \T)\D

\XD n36788$0' zD' %/ 8&D' Optimising stroke volume and oxygendelivery in abdominal aortic surgery: a randomised controlledtrial. B+/8 B48%6/1%63,& F+840' \T)kD 57K\LS .D )XZPZZD

\ZD n36788$0' zD' %/ 8&D' Haemodynamic optimisation in lower limbarterial surgery: room for improvement? B+/8 B48%6/1%63,&F+840' \T)kD 57K\LS .D )ZqPqZD

\qD 2%8$6%' ND"D' %/ 8&D' Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes followingmajor gastrointestinal surgery: a randomized clinical trial andsystematic review. zB"B' \T)UD

kTD F%487,$%' BDzD' %/ 8&D' Fluid management for laparoscopiccolectomy: a prospective, randomized assessment of goal-directed administration of balanced salt solution or hetastarchcoupled with an enhanced recovery program. *36 (,&,4 N%+/#-'\TTqD 52K)\LS .D )qkhPUTD

k)D *8>3%6' FDzD' %/ 8&D' Comparison of stroke volume and fluidresponsiveness measurements in commonly used technologiesfor goal-directed therapy. z (&34 B4%6/1' \T)kD

k\D "%47' GD' %/ 8&D' The impact of phenylephrine, ephedrine, andincreased preload on third-generation Vigileo-FloTrac andesophageal doppler cardiac output measurements. B4%6/1

B48&7' \T))D 113KULS .D Xh)PXDkkD 9,$06/$,-' zD' %/ 8&D' Stroke volume optimization in elective

bowel surgery: a comparison between pulse power waveanalysis (LiDCOrapid) and oesophageal Doppler (CardioQ). n$ z

B48%6/1' \T)kD 110KkLS .D kXUPZTD

kUD F+1&,7&1,?%$' OD' ED f3&&5' 840 ED F+13-8' Semi-invasivemeasurement of cardiac output based on pulse contour: areview and analysis. (84 z B48%6/1' \T)UD

khD E80384' "D' %/ 8&D' Cross-comparison of cardiac output trendingaccuracy of LiDCO, PiCCO, FloTrac and pulmonary arterycatheters. ($3/ (8$%' \T)TD 14KVLS .D N\)\D

kVD F347%$' "D' zD (&8$a%' 840 MD*D n%44%//' Continuoushemodynamic monitoring by esophageal Doppler. ($3/ (8$%"%0' )qZqD 17KhLS .D UUXPh\D

kXD "87#3$%' FD' %/ 8&D' Respiratory variation in pulse pressure and plethysmographic waveforms: intraoperative applicability in aNorth American academic center. B4%6/1 B48&7' \T))D 112K)LS .DqUPVD

dml meta-analysis v.1.3

Documents